Bristol Myers Squibb announced that the U.S. FDA has approved commercial production at the company’s newest cell therapy manufacturing facility in Devens, Massachusetts.
The new 244,000-square-foot cell therapy manufacturing facility is the second expansion of BMS’ 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics.
BMS began construction of the facility back in February 2021, as part of its investment to support clinical and commercial manufacturing of transformative cell therapies for patients with aggressive hematological cancers. The building of the facility coincided with the first approval of Breyanzi, the drugmaker's large B-cell lymphoma CAR-T therapy.
The Devens facility adds to the company’s global network of three state-of-the-art cell therapy manufacturing facilities in Bothell, Washington; Warren, New Jersey; and Summit, New Jersey, with another manufacturing site in development in Leiden, Netherlands. Like Devens, the Bothell and Summit sites are also FDA approved for commercial production.